A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome

Internal Medicine

Volumn 49, Issue 11, 2010, Pages 991-994

  Joshita, Satoru ^a   Yoshizawa, Kaname ^a   Sano, Kenji ^b   Kobayashi, Satoshi ^a   Sekiguchi, Tomohiro ^b   Morita, Susumu ^a   Kamijo, Atsushi ^a   Komatsu, Michiharu ^a   Umemura, Takeji ^a   Ichijo, Tetsuya ^a   Matsumoto, Akihiro ^a   Tanaka, Eiji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Sorafenib; Tumor lysis; Tumor lysis syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CALCIUM; LACTATE DEHYDROGENASE; MORPHINE; SORAFENIB; URIC ACID;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER PAIN; CANCER RADIOTHERAPY; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; ECHOGRAPHY; FATIGUE; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG PAIN; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR LYSIS SYNDROME; TUMOR VOLUME; URIC ACID BLOOD LEVEL;

ADULT; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES; TUMOR LYSIS SYNDROME;

EID: 77953346620     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3153     Document Type: Article

References (12)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
3. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 3: 438-447, 2006.
4. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3-11, 2004.
5. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880, 2004.
6. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77, 1998.
7. Yamaguchi R, Yano H, Nakashima O, et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 21: 152-160, 2006
8. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 103: 363-367, 1997.
9. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369: 1923-1924, 2007.
10. Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs 2009 [Epub ahead of print].
11. Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 25: 3544-3546, 2007.
12. Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 15: 4464-4466, 2009.